Skip to main content
Top
Published in: Tumor Biology 6/2016

Open Access 01-06-2016 | Original Article

Characterization of a new highly sensitive immunometric assay for thyroglobulin with reduced interference from autoantibodies

Authors: Marianne Nordlund Broughton, Ragnhild Nome, Ingvill Sandven, Elisabeth Paus, Trine Bjøro

Published in: Tumor Biology | Issue 6/2016

Login to get access

Abstract

Measurements of serum thyroglobulin (Tg) with sensitive immunoassays are of great importance for the management of patients with differentiated thyroid carcinomas. However, interference of circulating autoantibodies to Tg (hTgAb) hampers the usefulness of most assays. We have produced a panel of monoclonal antibodies (mAbs) selected to bind Tg in the presence of Tg autoantibodies and developed a sensitive immunoassay for Tg with minor interference by hTgAbs. The antibodies were characterized by cross-inhibition and immunoassay combination studies, as well as affinity estimation. The within-run and total imprecision of the assay were determined with 2664 samples in 60 separate runs. The most sensitive assay combination with superior protection against autoantibodies consisted of two solid phase mAbs and two tracer mAbs with distinct binding sites. The assay was linear and displayed a wide dynamic range up to 1342 μg/l with a functional sensitivity of 0.1 μg/l and a total imprecision of less than 10 %. There was good agreement between the new high sensitive immunofluorometric assay (IFMA) and two well-established Tg assays from Brahms Kryptor and Roche Diagnostics. Mean difference between the new IFMA and the Kryptor assay was 0.059 μg/l with a 95 % confidence interval of −0.032 to 0.151 μg/l, whereas the mean difference between the new IFMA and the Roche assay was −0.80 μg/l with a 95 % confidence interval of −1.24 to −0.35 μg/l.
Appendix
Available only for authorised users
Literature
1.
go back to reference Van Herle AJ, Vassart G, Dumont JE. Control of thyroglobulin synthesis and secretion (first of two parts). N Engl J Med. 1979;301(5):239–49.CrossRefPubMed Van Herle AJ, Vassart G, Dumont JE. Control of thyroglobulin synthesis and secretion (first of two parts). N Engl J Med. 1979;301(5):239–49.CrossRefPubMed
2.
go back to reference Van Herle AJ, Vassart G, Dumont JE. Control of thyroglobulin synthesis and secretion (second of two parts). N Engl J Med. 1979;301(6):307–14.CrossRefPubMed Van Herle AJ, Vassart G, Dumont JE. Control of thyroglobulin synthesis and secretion (second of two parts). N Engl J Med. 1979;301(6):307–14.CrossRefPubMed
3.
go back to reference Mazzaferri EL. Histologic variants of papillary thyroid carcinoma. Endocr Pract. 2001;7(2):139–42.CrossRefPubMed Mazzaferri EL. Histologic variants of papillary thyroid carcinoma. Endocr Pract. 2001;7(2):139–42.CrossRefPubMed
4.
go back to reference Pellegriti G, Frasca F, Regalbuto C, Squatrito S, Vigneri R. Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiol. 2013;2013:965212.CrossRefPubMedPubMedCentral Pellegriti G, Frasca F, Regalbuto C, Squatrito S, Vigneri R. Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiol. 2013;2013:965212.CrossRefPubMedPubMedCentral
5.
go back to reference Malandrino P, Latina A, Marescalco S, Spadaro A, Regalbuto C, Fulco RA, et al. Risk-adapted management of differentiated thyroid cancer assessed by a sensitive measurement of basal serum thyroglobulin. J Clin Endocrinol Metab. 2011;96(6):1703–9.CrossRefPubMed Malandrino P, Latina A, Marescalco S, Spadaro A, Regalbuto C, Fulco RA, et al. Risk-adapted management of differentiated thyroid cancer assessed by a sensitive measurement of basal serum thyroglobulin. J Clin Endocrinol Metab. 2011;96(6):1703–9.CrossRefPubMed
6.
go back to reference Chindris AM, Diehl NN, Crook JE, Fatourechi V, Smallridge RC. Undetectable sensitive serum thyroglobulin (<0.1 ng/ml) in 163 patients with follicular cell-derived thyroid cancer: results of rhTSH stimulation and neck ultrasonography and long-term biochemical and clinical follow-up. J Clin Endocrinol Metab. 2012;97(8):2714–23.CrossRefPubMed Chindris AM, Diehl NN, Crook JE, Fatourechi V, Smallridge RC. Undetectable sensitive serum thyroglobulin (<0.1 ng/ml) in 163 patients with follicular cell-derived thyroid cancer: results of rhTSH stimulation and neck ultrasonography and long-term biochemical and clinical follow-up. J Clin Endocrinol Metab. 2012;97(8):2714–23.CrossRefPubMed
7.
go back to reference Giovanella L, Feldt-Rasmussen U, Verburg FA, Grebe SK, Plebani M, Clark PM. Thyroglobulin measurement by highly sensitive assays: focus on laboratory challenges. Clin Chem Lab Med. 2014. Giovanella L, Feldt-Rasmussen U, Verburg FA, Grebe SK, Plebani M, Clark PM. Thyroglobulin measurement by highly sensitive assays: focus on laboratory challenges. Clin Chem Lab Med. 2014.
8.
go back to reference Spencer C, Petrovic I, Fatemi S, LoPresti J. Serum thyroglobulin (Tg) monitoring of patients with differentiated thyroid cancer using sensitive (second-generation) immunometric assays can be disrupted by false-negative and false-positive serum thyroglobulin autoantibody misclassifications. J Clin Endocrinol Metab. 2014;99(12):4589–99.CrossRefPubMedPubMedCentral Spencer C, Petrovic I, Fatemi S, LoPresti J. Serum thyroglobulin (Tg) monitoring of patients with differentiated thyroid cancer using sensitive (second-generation) immunometric assays can be disrupted by false-negative and false-positive serum thyroglobulin autoantibody misclassifications. J Clin Endocrinol Metab. 2014;99(12):4589–99.CrossRefPubMedPubMedCentral
9.
go back to reference Spencer C, Petrovic I, Fatemi S. Current thyroglobulin autoantibody (TgAb) assays often fail to detect interfering TgAb that can result in the reporting of falsely low/undetectable serum Tg IMA values for patients with differentiated thyroid cancer. J Clin Endocrinol Metab. 2011;96(5):1283–91.CrossRefPubMed Spencer C, Petrovic I, Fatemi S. Current thyroglobulin autoantibody (TgAb) assays often fail to detect interfering TgAb that can result in the reporting of falsely low/undetectable serum Tg IMA values for patients with differentiated thyroid cancer. J Clin Endocrinol Metab. 2011;96(5):1283–91.CrossRefPubMed
10.
go back to reference Stahli C, Staehelin T, Miggiano V, Schmidt J, Haring P. High frequencies of antigen-specific hybridomas: dependence on immunization parameters and prediction by spleen cell analysis. J Immunol Methods. 1980;32(3):297–304.CrossRefPubMed Stahli C, Staehelin T, Miggiano V, Schmidt J, Haring P. High frequencies of antigen-specific hybridomas: dependence on immunization parameters and prediction by spleen cell analysis. J Immunol Methods. 1980;32(3):297–304.CrossRefPubMed
11.
go back to reference Dajani LK, Paus E, Warren DJ. Development of a rapid and sensitive immunofluorometric assay for glutathione S-transferase A. Clin Chem. 2001;47(5):867–73.PubMed Dajani LK, Paus E, Warren DJ. Development of a rapid and sensitive immunofluorometric assay for glutathione S-transferase A. Clin Chem. 2001;47(5):867–73.PubMed
12.
go back to reference Milenic DE, Esteban JM, Colcher D. Comparison of methods for the generation of immunoreactive fragments of a monoclonal antibody (B72.3) reactive with human carcinomas. J Immunol Methods. 1989;120(1):71–83.CrossRefPubMed Milenic DE, Esteban JM, Colcher D. Comparison of methods for the generation of immunoreactive fragments of a monoclonal antibody (B72.3) reactive with human carcinomas. J Immunol Methods. 1989;120(1):71–83.CrossRefPubMed
13.
go back to reference Armbruster DA, Pry T. Limit of blank, limit of detection and limit of quantitation. Clin Biochem Rev. 2008;29 Suppl 1:S49–52.PubMedPubMedCentral Armbruster DA, Pry T. Limit of blank, limit of detection and limit of quantitation. Clin Biochem Rev. 2008;29 Suppl 1:S49–52.PubMedPubMedCentral
14.
go back to reference Bjerner J, Nustad K, Norum LF, Olsen KH, Bormer OP. Immunometric assay interference: incidence and prevention. Clin Chem. 2002;48(4):613–21.PubMed Bjerner J, Nustad K, Norum LF, Olsen KH, Bormer OP. Immunometric assay interference: incidence and prevention. Clin Chem. 2002;48(4):613–21.PubMed
15.
go back to reference Ruf J, Carayon P, Sarles-Philip N, Kourilsky F, Lissitzky S. Specificity of monoclonal antibodies against human thyroglobulin; comparison with autoimmune antibodies. EMBO J. 1983;2(10):1821–6.PubMedPubMedCentral Ruf J, Carayon P, Sarles-Philip N, Kourilsky F, Lissitzky S. Specificity of monoclonal antibodies against human thyroglobulin; comparison with autoimmune antibodies. EMBO J. 1983;2(10):1821–6.PubMedPubMedCentral
16.
go back to reference Piechaczyk M, Chardes T, Cot MC, Pau B, Bastide JM. Production and characterization of monoclonal antibodies against human thyroglobulin. Hybridoma. 1985;4(4):361–7.CrossRefPubMed Piechaczyk M, Chardes T, Cot MC, Pau B, Bastide JM. Production and characterization of monoclonal antibodies against human thyroglobulin. Hybridoma. 1985;4(4):361–7.CrossRefPubMed
17.
go back to reference Latrofa F, Phillips M, Rapoport B, McLachlan SM. Human monoclonal thyroglobulin autoantibodies: epitopes and immunoglobulin genes. J Clin Endocrinol Metab. 2004;89(10):5116–23.CrossRefPubMed Latrofa F, Phillips M, Rapoport B, McLachlan SM. Human monoclonal thyroglobulin autoantibodies: epitopes and immunoglobulin genes. J Clin Endocrinol Metab. 2004;89(10):5116–23.CrossRefPubMed
18.
go back to reference Lupoli GA, Okosieme OE, Evans C, Clark PM, Pickett AJ, Premawardhana LD, et al. Prognostic significance of thyroglobulin antibody epitopes in differentiated thyroid cancer. J Clin Endocrinol Metab. 2015;100(1):100–8.CrossRefPubMed Lupoli GA, Okosieme OE, Evans C, Clark PM, Pickett AJ, Premawardhana LD, et al. Prognostic significance of thyroglobulin antibody epitopes in differentiated thyroid cancer. J Clin Endocrinol Metab. 2015;100(1):100–8.CrossRefPubMed
19.
go back to reference Ruf J, Carayon P, Lissitzky S. Various expressions of a unique anti-human thyroglobulin antibody repertoire in normal state and autoimmune disease. Eur J Immunol. 1985;15(3):268–72.CrossRefPubMed Ruf J, Carayon P, Lissitzky S. Various expressions of a unique anti-human thyroglobulin antibody repertoire in normal state and autoimmune disease. Eur J Immunol. 1985;15(3):268–72.CrossRefPubMed
20.
go back to reference Piechaczyk M, Bouanani M, Salhi SL, Baldet L, Bastide M, Pau B, et al. Antigenic domains on the human thyroglobulin molecule recognized by autoantibodies in patients’ sera and by natural autoantibodies isolated from the sera of healthy subjects. Clin Immunol Immunopathol. 1987;45(1):114–21.CrossRefPubMed Piechaczyk M, Bouanani M, Salhi SL, Baldet L, Bastide M, Pau B, et al. Antigenic domains on the human thyroglobulin molecule recognized by autoantibodies in patients’ sera and by natural autoantibodies isolated from the sera of healthy subjects. Clin Immunol Immunopathol. 1987;45(1):114–21.CrossRefPubMed
21.
go back to reference Bouanani M, Piechaczyk M, Pau B, Bastide M. Significance of the recognition of certain antigenic regions on the human thyroglobulin molecule by natural autoantibodies from healthy subjects. J Immunol. 1989;143(4):1129–32.PubMed Bouanani M, Piechaczyk M, Pau B, Bastide M. Significance of the recognition of certain antigenic regions on the human thyroglobulin molecule by natural autoantibodies from healthy subjects. J Immunol. 1989;143(4):1129–32.PubMed
22.
go back to reference Rose NR, Bresler HS, Burek CL, Gleason SL, Kuppers RC. Mapping the autoepitopes of thyroglobulin. Isr J Med Sci. 1990;26(12):666–72.PubMed Rose NR, Bresler HS, Burek CL, Gleason SL, Kuppers RC. Mapping the autoepitopes of thyroglobulin. Isr J Med Sci. 1990;26(12):666–72.PubMed
23.
go back to reference Saboori AM, Caturegli P, Rose NR, Mariotti S, Pinchera A, Burek CL. Tryptic peptides of human thyroglobulin: II. Immunoreactivity with sera from patients with thyroid diseases. Clin Exp Immunol. 1994;98(3):459–63.CrossRefPubMedPubMedCentral Saboori AM, Caturegli P, Rose NR, Mariotti S, Pinchera A, Burek CL. Tryptic peptides of human thyroglobulin: II. Immunoreactivity with sera from patients with thyroid diseases. Clin Exp Immunol. 1994;98(3):459–63.CrossRefPubMedPubMedCentral
24.
go back to reference Iervasi A, Iervasi G, Ferdeghini M, Solimeo C, Bottoni A, Rossi L, et al. Clinical relevance of highly sensitive Tg assay in monitoring patients treated for differentiated thyroid cancer. Clin Endocrinol (Oxf). 2007;67(3):434–41.CrossRef Iervasi A, Iervasi G, Ferdeghini M, Solimeo C, Bottoni A, Rossi L, et al. Clinical relevance of highly sensitive Tg assay in monitoring patients treated for differentiated thyroid cancer. Clin Endocrinol (Oxf). 2007;67(3):434–41.CrossRef
25.
go back to reference Smallridge RC, Meek SE, Morgan MA, Gates GS, Fox TP, Grebe S, et al. Monitoring thyroglobulin in a sensitive immunoassay has comparable sensitivity to recombinant human TSH-stimulated thyroglobulin in follow-up of thyroid cancer patients. J Clin Endocrinol Metab. 2007;92(1):82–7.CrossRefPubMed Smallridge RC, Meek SE, Morgan MA, Gates GS, Fox TP, Grebe S, et al. Monitoring thyroglobulin in a sensitive immunoassay has comparable sensitivity to recombinant human TSH-stimulated thyroglobulin in follow-up of thyroid cancer patients. J Clin Endocrinol Metab. 2007;92(1):82–7.CrossRefPubMed
26.
go back to reference Spencer CA, LoPresti JS, Fatemi S, Nicoloff JT. Detection of residual and recurrent differentiated thyroid carcinoma by serum thyroglobulin measurement. Thyroid. 1999;9(5):435–41.CrossRefPubMed Spencer CA, LoPresti JS, Fatemi S, Nicoloff JT. Detection of residual and recurrent differentiated thyroid carcinoma by serum thyroglobulin measurement. Thyroid. 1999;9(5):435–41.CrossRefPubMed
27.
go back to reference Clark P, Franklyn J. Can we interpret serum thyroglobulin results? Ann Clin Biochem. 2012;49(Pt 4):313–22.CrossRefPubMed Clark P, Franklyn J. Can we interpret serum thyroglobulin results? Ann Clin Biochem. 2012;49(Pt 4):313–22.CrossRefPubMed
Metadata
Title
Characterization of a new highly sensitive immunometric assay for thyroglobulin with reduced interference from autoantibodies
Authors
Marianne Nordlund Broughton
Ragnhild Nome
Ingvill Sandven
Elisabeth Paus
Trine Bjøro
Publication date
01-06-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 6/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-4597-2

Other articles of this Issue 6/2016

Tumor Biology 6/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine